Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 2, 2016
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, explains the rationale and design of PlanB, a prospective phase 3 trial evaluating the Oncotype DX® 21-gene Recurrence Score® result for defining a low-risk subgroup of breast cancer patients with node-negative disease and high-risk clinicopathological factors as well as patients with node-positive disease who could be treated with adjuvant endocrine therapy alone.